Gilead Sciences has been knocked back in its quest to bring the first drug therapy for hepatitis D virus (HDV) to the US market, after the FDA rejected its marketing application. News of the ...

“This report highlights the continued progress toward eliminating hepatitis B, C, and D from Philadelphia," said Health Commissioner Dr. Palak Raval-Nelson. "Much work remains, however, and by ...